ACOT13 and fatty liver disease: Compound A1 treatment abrogated the WT Them2-induced increase in hepatic steatosis, as assessed by histopathology (Fig. 5A) and hepatic concentrations of triglycerides (Fig. 5B), total cholesterol (Fig. 5C), free cholesterol (Fig. 5D), free fatty acids (Fig. 5E) and diglycerides (Fig. 5F).